Taishi Onodera
Overview
Explore the profile of Taishi Onodera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
940
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fujisawa M, Onodera T, Kuroda D, Kewcharoenwong C, Sasaki M, Itakura Y, et al.
NPJ Vaccines
. 2025 Feb;
10(1):39.
PMID: 39988605
Rabies vaccines require repeated immunization to robustly elicit neutralizing antibodies that prevent fatal diseases. Here, we analyzed rabies glycoprotein antibody repertoires at both polyclonal and monoclonal levels following repeated vaccination....
2.
Kotaki R, Moriyama S, Oishi S, Onodera T, Adachi Y, Sasaki E, et al.
Sci Transl Med
. 2024 Aug;
16(761):eadp9927.
PMID: 39167666
Immunological imprinting by ancestral SARS-CoV-2 strains is thought to impede the robust induction of Omicron-specific humoral responses by Omicron-based booster vaccines. Here, we analyzed the specificity and neutralization activity of...
3.
Kewcharoenwong C, Freeouf S, Nithichanon A, Petsophonsakul W, Pornprasert S, Khamduang W, et al.
Med Microbiol Immunol
. 2024 May;
213(1):7.
PMID: 38761268
The incidence of rabies in Thailand reached its peak in 2018 with 18 human deaths. Preexposure prophylaxis (PrEP) vaccination is thus recommended for high-risk populations. WHO has recently recommended that...
4.
Inoue T, Yamamoto Y, Sato K, Okemoto-Nakamura Y, Shimizu Y, Ogawa M, et al.
iScience
. 2024 Mar;
27(4):109363.
PMID: 38500835
A current challenge is the emergence of SARS-CoV-2 variants, such as BQ.1.1 and XBB.1.5, that can evade immune defenses, thereby limiting antibody drug effectiveness. Emergency-use antibody drugs, including the widely...
5.
Moriyama S, Anraku Y, Taminishi S, Adachi Y, Kuroda D, Kita S, et al.
Nat Commun
. 2023 Jul;
14(1):4198.
PMID: 37452031
SARS-CoV-2 Omicron subvariants have evolved to evade receptor-binding site (RBS) antibodies that exist in diverse individuals as public antibody clones. We rationally selected RBS antibodies resilient to mutations in emerging...
6.
Fujisawa M, Adachi Y, Onodera T, Shiwa-Sudo N, Iwata-Yoshikawa N, Nagata N, et al.
Biochem Biophys Res Commun
. 2023 Jun;
673:114-120.
PMID: 37379800
SARS-CoV-2 nucleocapsid protein (NP) is the main target for COVID-19-diagnostic PCR and antigen rapid diagnostic tests (Ag-RDTs). Ag-RDTs are more convenient than PCR tests for point-of-care testing or self-testing to...
7.
Onodera T, Sax N, Sato T, Adachi Y, Kotaki R, Inoue T, et al.
Sci Adv
. 2023 Jun;
9(24):eadf0661.
PMID: 37315144
Severe acute respiratory syndrome coronavirus 2-neutralizing antibodies primarily target the spike receptor binding domain (RBD). However, B cell antigen receptors (BCRs) on RBD-binding memory B (B) cells have variation in...
8.
Takano T, Sato T, Kotaki R, Moriyama S, Fukushi S, Shinoda M, et al.
Nat Commun
. 2023 Mar;
14(1):1451.
PMID: 36922492
The immunogenicity of mRNA vaccines has not been well studied when compared to different vaccine modalities in the context of additional boosters. Here we show that longitudinal analysis reveals more...
9.
Yamamoto Y, Nakano Y, Murae M, Shimizu Y, Sakai S, Ogawa M, et al.
Int J Mol Sci
. 2023 Jan;
24(1).
PMID: 36613459
Peracetic acid (PAA) disinfectants are effective against a wide range of pathogenic microorganisms, including bacteria, fungi, and viruses. Several studies have shown the efficacy of PAA against severe acute respiratory...
10.
Shimojima M, Sugimoto S, Umekita K, Onodera T, Sano K, Tani H, et al.
Viruses
. 2022 Aug;
14(8).
PMID: 36016286
Severe fever with thrombocytopenia syndrome (SFTS) is an infectious disease with a high case fatality rate caused by the SFTS virus, and currently there are no approved specific treatments. Neutralizing...